Kempharm - ZVRA Net earnings per share growth forecast for next year

Corporate company logo of Zevra Therapeutics (ZVRA)

Zevra Therapeutics (ZVRA) is establishing a comprehensive environment for the therapy of rare neurological pathologies. Reviewing the history of forward earnings per share valuations on GURU.Markets, we see that -28.90 determines the latest valuation metric. Zevra Therapeutics relies on a proprietary drug development base for niche CNS markets, possessing significant pricing power. Current sales of approved products generate operational liquidity, stabilizing cash flows.

Kempharm (ZVRA): Net earnings per share growth forecast for next year from 04/28/2023 to 11/17/2026

Summary analytical data breakdowns for Kempharm (ZVRA)

- price and consensus price forecast:
Fundamental company analysis:Kempharm
Finished products of Zevra Therapeutics Inc

This indicator reflects the analysts' consensus forecast for the growth rate of earnings per share (EPS) for the coming year. It measures the dynamics of market expectation revisions, where the trend of EPS growth forecasts serves as a filter for market noise. A steady upward curve confirms the fundamental resilience of the business. For Zevra Therapeutics (ZVRA), this is critical: the scalability of orphan drugs allows the company to convert prescription growth into a high-margin cash flow.

Who Zevra Therapeutics competes with

Net earnings per share growth forecast for next year Jazz Pharmaceuticals|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Bio (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa Pharmaceuticals PLC CNTA|Dyne Pharma (DYN) - Expected net earnings per share growth next year|EWTX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Rapport Therapeutics, Inc.|ALMS: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Contineum Pharma CTNM|Expected earnings per share growth for next year LRMR|Expected net earnings per share growth next year Capricor Therapeutics CAPR|Earnings growth forecast for next year TRDA|Expected earnings per share growth for next year Channel Therapeutics PTHS|Earnings growth forecast for next year MNOV (MediciNova)|Expected earnings per share trend next year SER|BTAI - Net earnings per share growth forecast for next year|promisneurosciences.com (PMN) - Expected earnings per share growth for next year|Apimeds (APUS) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year AEON|Net earnings per share growth forecast for next year NLS Pharma|Expected net earnings per share growth next year bionomics.com.au BNOX|Earnings growth forecast for next year HUGE|RETA (Reata Pharma) - Expected earnings per share trend next year